Inhibitory Potential of Combination of Macrolide Antibiotic with Conventional Chemotherapeutic Agent Sorafenib on Growth Rate of Cancer Cell Population

Dabeeran Zehra,Kauser Ismail,Nabila Rasheed,Shumaila Usman,Syed Faizan Ali Rizvi,Syed Saud Hasan,Urooj Zafar

doi:10.9734/jpri/2021/v33i47b33124

Abstract

Over the past few years great progress has been achieved in anticancer therapy, but development of resistance and unavoidable side effects have incapacitated these fulfilments. Keeping in view this demanding condition, numerous drugs with unique antitumor mechanisms are under investigations including antimicrobials which have been shown to possess anti-inflammatory, immunomodulatory and cytotoxic effects. In this regard, both conventional and novel antimicrobials are being studied to explore their anticancer potential along with underlying mechanisms which may render them as effective anticancer drugs in near future. Moreover, the new approach of drug repurposing is also being encouraged especially in cancers in order to reduce cost and limit adverse effects. In recent times a cumulative number of studies have laid stress upon the antitumor properties of antimicrobials. Consequently, this study has been conducted to see comparative inhibitory effect of Sorafenib and its combination with a macrolide antibiotic Azithromycin on growth rate HepG2 cell line.

Highlights

Hepatocellular carcinoma (HCC) is one of the familiar cancers around the globe responsible for the highest rate of incidence in the region of East Asia and Africa [1].It stands as sixth most common malignancy worldwide [2] but due to poor prognosis it is third leading cause of cancer related mortality around the world [3] with adenocarcinoma of liver being the commonest type [4]
As cited by Intaraprasong et al in 2016, the median survival rate was enhanced from 7.9% to 10.7% in 602 patients suffering from HCC who received Sorafenib in comparison with placebo group
We are aiming to demonstrate the comparative potential of anticancer drug Sorafenib and its combination with a macrolide antibiotic, Azithromycin as a cell growth inhibitor of cancer cells in hepatoma cell line

Summary

Introduction

Hepatocellular carcinoma (HCC) is one of the familiar cancers around the globe responsible for the highest rate of incidence in the region of East Asia and Africa [1].It stands as sixth most common malignancy worldwide [2] but due to poor prognosis it is third leading cause of cancer related mortality around the world [3] with adenocarcinoma of liver being the commonest type [4]. Few drugs are available for managing HCC beside surgical or radiological interventions which improve median survival rate for few months, among which Sorafenib is the only FDA approved drug [5]. Uptill it is the only approved drug which progresses the overall median survival in liver cancer patients [4]. Several drugs like metformin and paracetamol revealed remarkable antiproliferative potential in certain in vitro studies [8]. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. We are aiming to demonstrate the comparative potential of anticancer drug Sorafenib and its combination with a macrolide antibiotic, Azithromycin as a cell growth inhibitor of cancer cells in hepatoma cell line

Methods

Results

Discussion

Conclusion